INTRODUCTION
The randomized phase III CRYSTAL (Cetuximab Combined With Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer) study showed that the addition of cetuximab to infusional fluorouracil, leucovorin,andirinotecan(FOLFIRI)significantlyimproved overall survival (OS) time, progression-free survival (PFS) time, and objective response rate in the first-line treatment of patients with KRAS codon 12 and 13 (hereinafter exon 2) wild-type metastatic colorectal cancer (mCRC). No cetuximab efficacy benefit wasapparentinthesubgroupofpatientswhosetumors carried such exon 2 mutations. 1, 2 In the same setting, the randomized phase II OPUS (Oxaliplatin and Cetuximab in First-Line Treatment of Metastatic Colorectal Cancer) study demonstrated that the addition of cetuximab to anotherstandardfirst-lineregimen-fluorouracil,leucovorin, and oxaliplatin (FOLFOX4)-significantly improved objective response rate and PFS time in patients with KRAS exon 2 wild-type tumors. However, it was reported that for patients with KRAS exon 2 tumor mutations, the addition of cetuximab to FOLFOX4 resulted in worse outcome compared with FOLFOX4 alone. 3, 4 Similar findings were also reported from the PRIME (Panitumumab Randomized Trial in Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy) study for another epidermal growth factor receptor (EGFR) antibody, panitumumab, which improved outcome in patients when combined with FOLFOX4 in the first-line treatment of KRAS exon 2 wild-type mCRC. As for cetuximab, a negative effect was apparent when panitumumab was combined with FOLFOX4 in patients with KRAS exon 2 mutations. 5 Activating missense mutations of KRAS at codons other than 12 or 13 have been identified in a wide range of tumor types, including CRC. 6 Similar somatic tumor mutations have also been detected at corresponding loci within the NRAS gene. A retrospective analysis of the PRIME study demonstrated that a subgroup of 17.4% of patients with KRAS exon 2 wild-type mCRC had tumor mutations at another RAS locus (KRAS codons 61, 117, and 146; NRAS codons 12, 13, and 61). Such other RAS mutations were associated negatively with outcome in patients receiving FOLFOX4 plus panitumumab. 7 Exploratory analysis further suggested that RAS codon 59 mutations might also be negative biomarkers for panitumumab efficacy.
The primary objective of our post hoc investigation was to assess the treatment effect of FOLFIRI plus cetuximab compared with FOLFIRI alone in patients with tumors carrying predefined mutations at RAS loci other than KRAS codon 12 or 13 (other RAS mutations). Also assessed was the treatment effect in patients with evaluable tumors wild type at all RAS loci.
PATIENTS AND METHODS

Study Design and Treatment
The phase III CRYSTAL study compared 14-day cycles of FOLFIRI plus weekly cetuximab with FOLFIRI alone as first-line treatment for patients with EGFR-expressing mCRC. Treatment was continued until disease progression, unacceptable toxicity, or withdrawal of consent. The primary end point was PFS, as determined by independent review. The clinical study was approved by the independent ethics committee of each trial center and was carried out in accordance with the Declaration of Helsinki. Eligibility criteria have been described previously. 1 All patients provided informed consent before inclusion. A previous retrospective subgroup analysis investigated the association of tumor KRAS exon 2 mutation status and treatment outcome. 2
RAS Mutation Testing
Extended RAS mutation testing was performed on DNA samples extracted previously from formalin-fixed paraffin-embedded tumor tissue sections from CRYSTAL study patients and which had been scored in earlier investigations as wild type at codons 12 and 13 of KRAS. 2 Before DNA extraction, stained slides were reviewed by a pathologist to estimate overall neoplastic cell content; no exclusion criteria were applied. The estimated fraction of neoplastic cells was between 5% and 60% for most samples. Because the polymerase chain reaction clamping and melting curve technique used in the original testing was a highly sensitive method designed to enrich for mutant over wild-type sequences, 1,8 macro-or microdissection of tissue sections was not carried out. In the application of the 5% cutoff in our analysis, the estimated fraction of neoplastic cells was not taken into consideration. Ploidy status, which was not assessed, was also not taken into consideration.
The highly sensitive beads, emulsion, amplification, and magnetics (BEAM) technology was selected for the RAS mutation analysis to take into account the source and nature of the tumor DNA available (Data Supplement). 9 This approach can detect and enumerate mutant versus wild-type DNA sequences at ratios down to 1:10,000 (0.01%). 10, 11 RAS testing was carried out by a contract research organization (Sysmex Inostics, Hamburg, Germany). .47
Randomly assigned and treated
Best overall response † Complete The presence of 26 specific mutations reported in the Catalogue of Somatic Mutations in Cancer and/or Cancer Genome Atlas databases within KRAS exons 3 (codons 59 and 61) and 4 (codons 117 and 146) and NRAS exons 2 (codons 12 and 13), 3 (codons 59 and 61), and 4 (codons 117 and 146) was investigated (Data Supplement). Samples were not reassessed for the presence of KRAS exon 2 (codons 12 and 13) mutations.
Statistical Analysis
For each evaluable sample, the fraction of mutant RAS alleles was calculated by dividing the number of mutant beads by the total number of beads with polymerase chain reaction product (sum of mutant, wild-type, and mutant/wild-type beads). Broadly in line with the sensitivity of other approaches that might be used clinically to assign RAS mutation status, and after an initial evaluation of the impact of using alternative cutoff values, tumors were scored as RAS mutant if the sum of the individual percentages of mutant sequences over total amplified sequences for the analyzed loci was Ն 5%, regardless of whether all loci were evaluable for mutation status. Tumors were scored as RAS wild type only if all 26 mutation assays were evaluable and the summed prevalence of mutations across all loci was Ͻ 5%.
The primary objective of our post hoc analysis was to investigate the treatment effect of FOLFIRI plus cetuximab compared with FOLFIRI alone in patients with tumor RAS mutations other than KRAS exon 2 (other RAS). This extended analysis was limited to those CRYSTAL study patients for whom an evaluable tumor DNA sample was available. Outcome for patients with tumors wild type at all tested RAS loci was also investigated. Treatment outcome in patients with any RAS mutation, comprising those with either previously identified KRAS exon 2 mutations (not reassessed in our study) or other RAS mutations, was also analyzed. Outcome in patients wild type for both RAS and BRAF (V600E; as previously defined 2 ) was considered. The treatment effect in different other RAS-mutant populations, as defined according to a range of diagnostic cutoffs from 0.1% to 20%, was visualized using forest plots of hazard ratios (HRs) and odds ratios (ORs).
HRs and ORs were calculated for FOLFIRI plus cetuximab versus FOLFIRI alone. For OS and PFS, HRs and 95% CIs for treatment comparisons were calculated using univariable Cox proportional hazards models. Median survival times were estimated using the Kaplan-Meier method 12 (productlimit estimates), and P values were calculated using log-rank tests. For objective response, treatment groups were compared using Cochran-Mantel-Haenszel tests. All analyses, apart from those for different cutoff values as presented in the forest plots, were stratified according to Eastern Cooperative Oncology Group performance status and region, as assigned through the interactive voice response system at random assignment.
RESULTS
Patients and Samples
Of the 666 CRYSTAL study patients with tumors previously typed as KRAS exon 2 wild type, RAS tumor mutation status was evaluable in 430 (64.6%; Fig 1) . Samples from the remaining 236 patients were not evaluable, either because of insufficient residual DNA or because of the failure of Ն 1 mutation assay. Using a 5% mutant/wild-type cutoff, other RAS mutations were scored in 63 (14.7%) of 430 patients. Those with other RAS mutations were grouped with patients previously classified as having tumors with KRAS exon 2 mutations (n ϭ 397) to comprise a combined population of patients with any RAS mutations (n ϭ 460). Using the less stringent cutoff of Ն 0.1% mutant/wild-type sequences, other RAS mutations were scored in 86 (20.0%) of 430 patients. The most common site of other RAS mutations was within KRAS exon 4 (Data Supplement).
Of 422 RAS/BRAF evaluable tumors, 46 (10.9%) were known to carry BRAF mutations, all but one of which were scored as RAS wild type; 315 (74.6%) of 422 tumors were wild type for both RAS and BRAF. 
Comparability of Evaluable Populations
Baseline characteristics of the RAS-evaluable population and RAS wild-type and other RAS-mutant subgroups were broadly similar to those of the KRAS exon 2 wild-type subgroup of the KRAS population (Table 1) . However, and although balanced between treatment groups, notably fewer patients with a tumor RAS mutation (68 [14.8%]of 460) had received prior adjuvant chemotherapy compared with those with RAS wild-type tumors (82 [22.3%] of 367).
In relation to efficacy, there was a trend for better outcome for the FOLFIRI-plus-cetuximab group compared with the FOLFIRI-alone group in the RAS-evaluable population compared with the KRAS exon 2 wild-type population, with the difference most pronounced in relation to PFS and objective response (Table 2; Fig 2) . Given the similarity in baseline characteristics between the KRAS exon 2 wildtype population and the RAS-evaluable subset, there was no obvious selection bias that might have explained the increased cetuximab benefit in the RAS-evaluable population.
Efficacy According to RAS Mutation Status
A clear and significant benefit associated with the addition of cetuximab to FOLFIRI was apparent in relation to OS, PFS, and objective response in patients with RAS wild-type tumors (n ϭ 367; efficacy outcome summarized in Table 2 and Figs 2 to 4). The HR for OS time and OR for objective response rate were more favorable toward FOLFIRI plus cetuximab in the RAS wild-type population than in the RAS-evaluable population. Setting aside the possible issue of selection bias, results for the RAS wild-type/BRAF wild-type population were similar to those of the RAS wild-type population (Data Supplement). For patients with tumors harboring other RAS mutations (n ϭ 63), no clear cetuximab treatment benefit was apparent. Efficacy outcomes were also investigated for the group of patients with any RAS mutation (n ϭ 460). No clear difference in efficacy outcome between treatment groups was apparent in this population.
BEAMing analysis allowed for the detection of tumor RAS mutations at low prevalence. Using a more sensitive threshold of 0.1% to call mutations, 23 (5.3%) of 430 tumors classified as RAS wild type when using a 5% cutoff were instead scored as RAS mutant. Efficacy outcomes were reassessed in RAS wild-type and RAS-mutant populations, as defined according to this 0.1% cutoff (Data Supplement). As for the 5% cutoff analysis, HRs and ORs did Treatment outcome in other RAS-mutant populations defined according to cutoff values of 20%, 10%, 5%, 1%, and 0.1% were visualized using forest plots of HRs for OS and PFS times and ORs for objective response rates (Data Supplement). These plots suggested that there was a relationship between the fraction of RAS-mutated neoplastic cells in a tumor and the strength of EGFR-targeted therapy resistance and that patients with other tumor RAS mutation signals between 0.1% and Ͻ 5% may have benefited from the addition of cetuximab to FOLFIRI.
Safety
The overall incidence of adverse events according to treatment group was broadly similar across the KRAS and RAS subgroups ( Table  3 ). In addition, the incidence of commonly reported adverse events in each treatment group was also generally similar across these populations and in line with expectations.
DISCUSSION
The aim of our post hoc analysis of the CRYSTAL study was to investigate the impact of RAS mutations other than KRAS codon 12 or 13 in relation to treatment effects. In the evaluable patients with other tumor RAS mutations, there was no clear evidence that the addition of cetuximab to FOLFIRI modified efficacy outcome. However, given the relatively small number of patients in this group, no definitive conclusions on the negative predictive value of other RAS mutations can be drawn. In the combined group of patients with any RAS mutation (KRAS exon 2 or other RAS), there was no indication that the addition of cetuximab to FOLFIRI either improved or worsened outcome. The absence of a negative effect in the RAS-mutant subgroup when cetuximab was combined with FOLFIRI in our study contrasts strongly with the data from the OPUS 13 and PRIME 7 RAS investigations, which suggested worse outcome in the RAS-mutant subgroups associated with the addition of cetuximab (PFS: HR, 1.54; 95% CI, 1.04 to 2.29) or panitumumab (PFS: HR, 1.31; 95% CI, 1.07 to 1.60 and OS: HR, 1.25; 95% CI, 1.02 to 1.55), respectively, to FOLFOX4. However, our data are in line with findings in the secondline setting, which showed that there was no negative effect of combining panitumumab with FOLFIRI for patients with KRAS exon 2-mutant or other RAS-mutant tumors. 14, 15 Furthermore, on the basis of the findings from these studies, current clinical guidelines recommend that only patients with RAS wild-type tumors should be treated with cetuximab or panitumumab in combination with FOLFIRI or FOLFOX chemotherapy. 16 In patients with RAS wild-type tumors, a clear cetuximab benefit was seen across efficacy end points. However, it should be noted in this context that an increased cetuximab benefit was apparent in the RASevaluable subgroup, compared with the overall KRAS exon 2 wildtype population, regardless of RAS status. Despite the similarity of baseline characteristics, selection bias in relation to the RAS-evaluable subgroup cannot be excluded.
The method selected to screen for RAS mutations was the BEAMing technique. 9 Although this approach can detect KRAS exon 2 mutations at a level of 0.01% mutant to wild-type sequences, 17 a higher threshold of Ն 5% was used in our RAS study. This is broadly in line with the sensitivity of other techniques such as next-generation sequencing, pyrosequencing, and dideoxy nucleotide sequencing, which may be used clinically to determine RAS mutation status. Because the fraction of neoplastic cells and ploidy status were not taken into account, the percentage of mutated cells cannot be estimated.
Using this cutoff, RAS mutations were scored in 14.7% of evaluable CRYSTAL study patients with KRAS exon 2 wild-type tumors. This frequency is similar to those reported in other first-line mCRC studies, which used pyrosequencing or dideoxy sequencing/WAVE analysis. 7, 18, 19 In common with these studies and also the parallel RAS analysis of the OPUS study, 13 the most common location of RAS mutations outside of KRAS exon 2 in CRYSTAL study patients was KRAS exon 4. Also of interest in relation to the mutation profile was that NRAS exon 4 tumor mutations, which were scored in four CRYS-TAL study patients when using the 5% cutoff and in 12 patients when using the 0.1% cutoff, had not to our knowledge been reported previously in the tumors of patients receiving first-line treatment for mCRC. NRAS exon 4 tumor mutations were also seen in the OPUS study RAS analysis, 13 in which an identical BEAMing mutation detection approach was used; again, the incidence was higher when 0.1% rather than 5% was used as a cutoff. It may be that such mutations tend to be of low prevalence and, although present, may not have been detected by other screening technologies.
Because the significance of low-prevalence KRAS or RAS mutations in relation to the effectiveness of EGFR antibody therapy in mCRC is not clear, 20-23 we also explored treatment outcome in RAS subgroups defined according to a threshold of 0.1% mutant to wildtype sequences. The effect of using the lower cutoff (higher sensitivity in relation to mutation identification) was to move 23 patients previously classified as RAS wild type to the mutant group. This resulted in essentially no change in the HRs or ORs for FOLFIRI plus cetuximab over FOLFIRI alone in the revised RAS wild-type population and marginally better outcome for the FOLFIRI-plus-cetuximab group in the revised other RAS-mutant population. These data are therefore consistent with patients with low-prevalence mutations (between 0.1% and Ͻ 5% mutant to wild type) deriving a treatment benefit from the addition of cetuximab to FOLFIRI. This conclusion is in line with the findings from a retrospective study of 95 patients with mCRC who had received EGFR antibody therapy, which indicated that the PFS of patients with tumors with low-prevalence KRAS mutations (Ͻ 5%) was comparable to that of patients with KRAS wild-type tumors. 21 Using higher cutoff levels resulted in too few patients for meaningful interpretations, but our forest plots suggest that the higher the fraction of mutated cells, the stronger the resistance to EGFR antibody treatment. This would be in line with the hypothesis that acquired resistance to such agents may result, at least in part, from the outgrowth of small numbers of cells with existing RAS mutations. 20 The CRYSTAL study data are therefore consistent with Ͻ 5% mutant sequences being a potentially appropriate cutoff value for determining eligibility for FOLFIRI plus cetuximab as first-line treatment. Nevertheless, more data and more precise measurements of the fraction of mutated neoplastic cells, as well as an accurate definition of the association between the fraction of mutated cells and resistance to EGFR monoclonal antibodies, are needed to define the optimal cutoff for the clinical setting. This would require large collaborative studies using common standardized methodologies for tumor processing and RAS mutation detection.
In summary, our study supports the use of FOLFIRI plus cetuximab in patients with RAS wild-type tumors and, on the basis of a lack of observed benefit, suggests the exclusion of patients with other RAS mutations. Reserving such first-line treatment for a RAS wild-type population allows the definition of a subgroup more likely to benefit from the addition of cetuximab to FOLFIRI. Molecular testing of tumors for all activating mutations in KRAS and NRAS before considering anti-EGFR therapy is therefore essential in selecting the most effective treatment for patients with mCRC.
AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
Disclosures provided by the authors are available with this article at www.jco.org. 
AUTHOR CONTRIBUTIONS
